Human iPSC-derived Disease Models for Drug Discovery

CHF 229.65
Auf Lager
SKU
VG4738R61H5
Stock 1 Verfügbar
Geliefert zwischen Mi., 21.01.2026 und Do., 22.01.2026

Details

Since their development a decade ago, human induced pluripotent stem cells (iPSC) have revolutionized the study of human disease, given rise to regenerative medicine technologies, and provided exceptional opportunities for pharmacologic research. These cells provide an essentially unlimited supply of cell types that are difficult to obtain from patients, such as neurons or cardiomyocytes, or are difficult to maintain in primary cell culture. iPSC can be obtained from patients afflicted with a particular disease but, in combination with recently developed gene editing techniques, can also be modified to generate disease models. Moreover, the new techniques of 3 Dimensional printing and materials science facilitate the generation of organoids that can mirror organs under disease conditions. These properties make iPSC powerful tools to study how diseases develop and how they may be treated. In addition, iPSC can also be used to treat conditions in which the target cell population has beenlost and such regenerative approaches hold great promise for currently untreatable diseases, including cardiac failure or photoreceptor degenerations.

Provides an exhaustive review of use of iPSC in pharmaceutics, iPSC-based modeling and materials science Broadens your understanding of iPSC to model diseases of cardiovascular system, nervous system and ophthalmology Presents iPSC-derived disease models that accelerate the development of pharmacologic treatments

Inhalt
Part 1 General considerations.- Human iPS for clinical applications and cellular products.- 3D-printed iPS disease models.- Part 2 CNS iPSC and organoids.- iPS-derived neurons and brain organoids from patients (brain).- iPS-derived RGCs (eye).- iPS-derived glia (brain).- iPSC to model blood-brain barrier endothelial cells.- Part 3 iPSC-derived nociceptive neurons.- IPSC-based peripheral nerve modeling.- Part 4 Non-neuronal specialized cell types.- iPSC-based drug screening of differentiated cardiomyocyte subtypes.- iPSC-based cardiac disease modeling: from cell to tissue.- iPSC-derived corneal endothelial cell.- iPSC-derived trabecular meshwork (eye).- iPSC for in vitro disease modeling of diabetes.

Weitere Informationen

  • Allgemeine Informationen
    • GTIN 09783031423482
    • Editor Markus H. Kuehn, Wei Zhu
    • Sprache Englisch
    • Größe H241mm x B160mm x T23mm
    • Jahr 2023
    • EAN 9783031423482
    • Format Fester Einband
    • ISBN 3031423488
    • Veröffentlichung 24.11.2023
    • Titel Human iPSC-derived Disease Models for Drug Discovery
    • Untertitel Handbook of Experimental Pharmacology 281
    • Gewicht 738g
    • Herausgeber Springer
    • Anzahl Seiten 340
    • Lesemotiv Verstehen
    • Genre Medical Books

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470